Development of Fluorescence-Based Assays for Key Viral Proteins in the SARS-CoV-2 Infection Process and Lifecycle

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Mar 13

PMID 38474097

Authors

Mingzhenlong Deng

Chuang Zhang

Wanli Yan

Lei Chen

Bin He

Yan Li

Affiliations

Soon will be listed here.

Abstract

Since the appearance of SARS-CoV-2 in 2019, the ensuing COVID-19 (Corona Virus Disease 2019) pandemic has posed a significant threat to the global public health system, human health, life, and economic well-being. Researchers worldwide have devoted considerable efforts to curb its spread and development. The latest studies have identified five viral proteins, spike protein (Spike), viral main protease (3CLpro), papain-like protease (PLpro), RNA-dependent RNA polymerase (RdRp), and viral helicase (Helicase), which play crucial roles in the invasion of SARS-CoV-2 into the human body and its lifecycle. The development of novel anti-SARS-CoV-2 drugs targeting these five viral proteins holds immense promise. Therefore, the development of efficient, high-throughput screening methodologies specifically designed for these viral proteins is of utmost importance. Currently, a plethora of screening techniques exists, with fluorescence-based assays emerging as predominant contenders. In this review, we elucidate the foundational principles and methodologies underpinning fluorescence-based screening approaches directed at these pivotal viral targets, hoping to guide researchers in the judicious selection and refinement of screening strategies, thereby facilitating the discovery and development of lead compounds for anti-SARS-CoV-2 pharmaceuticals.

Citing Articles

Research Progress on the Structure and Function, Immune Escape Mechanism, Antiviral Drug Development Methods, and Clinical Use of SARS-CoV-2 M.

Ren J, Zhang Z, Xia Y, Zhao D, Li D, Zhang S Molecules. 2025; 30(2).

PMID: 39860219 PMC: 11767629. DOI: 10.3390/molecules30020351.

A Gaussia luciferase reporter assay for the evaluation of coronavirus Nsp5/3CLpro activity.

Vlachou A, Nchioua R, Regensburger K, Kirchhoff F, Kmiec D Sci Rep. 2024; 14(1):20697.

PMID: 39237598 PMC: 11377810. DOI: 10.1038/s41598-024-71305-6.

References

Suh J, Kim H, Kim T . Development of a SARS-CoV-2-derived receptor-binding domain-based ACE2 biosensor. Sens Actuators B Chem. 2021; 334:129663. PMC: 7885701. DOI: 10.1016/j.snb.2021.129663. View

Haga K, Takai-Todaka R, Sawada A, Katayama K . Luciferase-based quantification of membrane fusion induced by SARS-CoV-2 S protein. Genes Cells. 2022; 27(8):537-543. PMC: 9347681. DOI: 10.1111/gtc.12945. View

Tian L, Qiang T, Liang C, Ren X, Jia M, Zhang J . RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic. Eur J Med Chem. 2021; 213:113201. PMC: 7826122. DOI: 10.1016/j.ejmech.2021.113201. View

Marx S, Mickolajczyk K, Craig J, Thomas C, Pfeffer A, Abell S . Observing inhibition of the SARS-CoV-2 helicase at single-nucleotide resolution. Nucleic Acids Res. 2023; 51(17):9266-9278. PMC: 10516658. DOI: 10.1093/nar/gkad660. View

Abian O, Ortega-Alarcon D, Jimenez-Alesanco A, Ceballos-Laita L, Vega S, Reyburn H . Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Int J Biol Macromol. 2020; 164:1693-1703. PMC: 7395220. DOI: 10.1016/j.ijbiomac.2020.07.235. View

Weiss S, Navas-Martin S . Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005; 69(4):635-64. PMC: 1306801. DOI: 10.1128/MMBR.69.4.635-664.2005. View

OBrien A, Chen D, Hackbart M, Close B, OBrien T, Saeed M . Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor. Virology. 2021; 556:73-78. PMC: 7837110. DOI: 10.1016/j.virol.2021.01.010. View

Bertolin A, Weissmann F, Zeng J, Posse V, Milligan J, Canal B . Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase. Biochem J. 2021; 478(13):2425-2443. PMC: 8286815. DOI: 10.1042/BCJ20210200. View

Adedeji A, Sarafianos S . Antiviral drugs specific for coronaviruses in preclinical development. Curr Opin Virol. 2014; 8:45-53. PMC: 4195804. DOI: 10.1016/j.coviro.2014.06.002. View

10.

Adedeji A, Singh K, Calcaterra N, DeDiego M, Enjuanes L, Weiss S . Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. Antimicrob Agents Chemother. 2012; 56(9):4718-28. PMC: 3421890. DOI: 10.1128/AAC.00957-12. View

11.

Shannon A, Le N, Selisko B, Eydoux C, Alvarez K, Guillemot J . Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020; 178:104793. PMC: 7151495. DOI: 10.1016/j.antiviral.2020.104793. View

12.

Girgis A, Panda S, Kariuki B, Bekheit M, Barghash R, Aboshouk D . Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2. Molecules. 2023; 28(18). PMC: 10537473. DOI: 10.3390/molecules28186603. View

13.

Uppal T, Tuffo K, Khaiboullina S, Reganti S, Pandori M, Verma S . Screening of SARS-CoV-2 antivirals through a cell-based RNA-dependent RNA polymerase (RdRp) reporter assay. Cell Insight. 2023; 1(4):100046. PMC: 9239919. DOI: 10.1016/j.cellin.2022.100046. View

14.

Mathieu C, Touret F, Jacquemin C, Janin Y, Nougairede A, Brailly M . A Bioluminescent 3CL Activity Assay to Monitor SARS-CoV-2 Replication and Identify Inhibitors. Viruses. 2021; 13(9). PMC: 8473059. DOI: 10.3390/v13091814. View

15.

Larue R, Xing E, Kenney A, Zhang Y, Tuazon J, Li J . Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2. Bioconjug Chem. 2020; 32(1):215-223. PMC: 7784661. DOI: 10.1021/acs.bioconjchem.0c00664. View

16.

Cecon E, Burridge M, Cao L, Carter L, Ravichandran R, Dam J . SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET. Cell Chem Biol. 2021; 29(1):74-83.e4. PMC: 8249686. DOI: 10.1016/j.chembiol.2021.06.008. View

17.

Yang H, Rao Z . Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol. 2021; 19(11):685-700. PMC: 8447893. DOI: 10.1038/s41579-021-00630-8. View

18.

Pozzi C, Vanet A, Francesconi V, Tagliazucchi L, Tassone G, Venturelli A . Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective. J Med Chem. 2023; 66(6):3664-3702. PMC: 10005815. DOI: 10.1021/acs.jmedchem.2c01229. View

19.

Smith E, Davis-Gardner M, Garcia-Ordonez R, Nguyen T, Hull M, Chen E . High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2. SLAS Discov. 2020; 25(10):1152-1161. PMC: 7550789. DOI: 10.1177/2472555220963667. View

20.

Mangiavacchi F, Botwina P, Menichetti E, Bagnoli L, Rosati O, Marini F . Seleno-Functionalization of Quercetin Improves the Non-Covalent Inhibition of M and Its Antiviral Activity in Cells against SARS-CoV-2. Int J Mol Sci. 2021; 22(13). PMC: 8268238. DOI: 10.3390/ijms22137048. View